Neutralizing Human Monoclonal Antibodies to Severe Acute Respiratory Syndrome Coronavirus: Target, Mechanism of Action and Therapeutic Potential
Identifieur interne : 002381 ( Ncbi/Curation ); précédent : 002380; suivant : 002382Neutralizing Human Monoclonal Antibodies to Severe Acute Respiratory Syndrome Coronavirus: Target, Mechanism of Action and Therapeutic Potential
Auteurs : Melissa M. Coughlin ; Bellur S. PrabhakarSource :
- Reviews in Medical Virology [ 1052-9276 ] ; 2011.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps antiviraux (isolement et purification), Anticorps monoclonaux (immunologie), Anticorps monoclonaux (isolement et purification), Anticorps neutralisants (immunologie), Anticorps neutralisants (isolement et purification), Antiviraux (isolement et purification), Antiviraux (pharmacologie), Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (antagonistes et inhibiteurs), Glycoprotéines membranaires (immunologie), Humains, Immunothérapie (), Liaison aux protéines, Protéines de l'enveloppe virale (antagonistes et inhibiteurs), Protéines de l'enveloppe virale (immunologie), Souris, Souris transgéniques, Syndrome respiratoire aigu sévère (), Virus du SRAS (immunologie), Épitopes (immunologie).
- MESH :
- antagonistes et inhibiteurs : Glycoprotéines membranaires, Protéines de l'enveloppe virale.
- immunologie : Anticorps antiviraux, Anticorps monoclonaux, Anticorps neutralisants, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Virus du SRAS, Épitopes.
- isolement et purification : Anticorps antiviraux, Anticorps monoclonaux, Anticorps neutralisants, Antiviraux.
- pharmacologie : Antiviraux.
- Animaux, Glycoprotéine de spicule des coronavirus, Humains, Immunothérapie, Liaison aux protéines, Souris, Souris transgéniques, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (isolation & purification), Antibodies, Neutralizing (immunology), Antibodies, Neutralizing (isolation & purification), Antibodies, Viral (immunology), Antibodies, Viral (isolation & purification), Antiviral Agents (isolation & purification), Antiviral Agents (pharmacology), Epitopes (immunology), Humans, Immunotherapy (methods), Membrane Glycoproteins (antagonists & inhibitors), Membrane Glycoproteins (immunology), Mice, Mice, Transgenic, Protein Binding, SARS Virus (immunology), Severe Acute Respiratory Syndrome (therapy), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (antagonists & inhibitors), Viral Envelope Proteins (immunology).
- MESH :
- chemical , antagonists & inhibitors : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Epitopes, Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , isolation & purification : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- immunology : SARS Virus.
- methods : Immunotherapy.
- therapy : Severe Acute Respiratory Syndrome.
- Animals, Humans, Mice, Mice, Transgenic, Protein Binding, Spike Glycoprotein, Coronavirus.
Abstract
The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) led to a rapid response not only to contain the outbreak but also to identify possible therapeutic interventions, including the generation of human monoclonal antibodies (hmAbs). Human mAbs may be used therapeutically without the drawbacks of chimeric or animal Abs. Several different methods have been used to generate SARS-CoV specific neutralizing hmAbs including the immunization of transgenic mice, cloning of small chain variable regions from naïve and convalescent patients, and the immortalization of convalescent B cells. Irrespective of the techniques used, the majority of hmAbs specifically reacted with the receptor binding domain (RBD) of the spike (S) protein and likely prevented receptor binding. However, several hmAbs that can bind to epitopes either within the RBD, located N terminal of the RBD or in the S2 domain and neutralize the virus with or without inhibiting receptor binding have been identified. Therapeutic utility of hmAbs has been further elucidated through the identification of potential combinations of hmAbs that could neutralize viral variants including escape mutants selected using hmAbs. These results suggest that a cocktail of hmAbs which can bind to unique epitopes and have different mechanisms of action might be of clinical utility against SARS-CoV infection, and indicate that a similar approach may be applied to treat other viral infections.
Url:
DOI: 10.1002/rmv.706
PubMed: 21905149
PubMed Central: 3256278
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C23
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000C23
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000B33
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001475
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001475
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001322
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002381
Links to Exploration step
PMC:3256278Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neutralizing Human Monoclonal Antibodies to Severe Acute Respiratory Syndrome Coronavirus: Target, Mechanism of Action and Therapeutic Potential</title>
<author><name sortKey="Coughlin, Melissa M" sort="Coughlin, Melissa M" uniqKey="Coughlin M" first="Melissa M." last="Coughlin">Melissa M. Coughlin</name>
<affiliation><nlm:aff id="A1">Centers for Disease Control and Prevention, Measles, Mumps, Rubella and Herpes Virus Laboratory Branch. 1600 Clifton Rd, C22, Atlanta, GA 30319.<email>mcoughlin@cdc.gov</email>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S." last="Prabhakar">Bellur S. Prabhakar</name>
<affiliation><nlm:aff id="A2">Department of Microbiology and Immunology MC790, College of Medicine, University of Illinois at Chicago, Room E705, 835 S. Wolcott Ave, Chicago, IL 60612.<email>bprabhak@uic.edu</email>
</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">21905149</idno>
<idno type="pmc">3256278</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256278</idno>
<idno type="RBID">PMC:3256278</idno>
<idno type="doi">10.1002/rmv.706</idno>
<date when="2011">2011</date>
<idno type="wicri:Area/Pmc/Corpus">000C23</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000C23</idno>
<idno type="wicri:Area/Pmc/Curation">000C23</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000C23</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000B33</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000B33</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21905149</idno>
<idno type="wicri:Area/PubMed/Corpus">001475</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001475</idno>
<idno type="wicri:Area/PubMed/Curation">001475</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001475</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001322</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001322</idno>
<idno type="wicri:Area/Ncbi/Merge">002381</idno>
<idno type="wicri:Area/Ncbi/Curation">002381</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Neutralizing Human Monoclonal Antibodies to Severe Acute Respiratory Syndrome Coronavirus: Target, Mechanism of Action and Therapeutic Potential</title>
<author><name sortKey="Coughlin, Melissa M" sort="Coughlin, Melissa M" uniqKey="Coughlin M" first="Melissa M." last="Coughlin">Melissa M. Coughlin</name>
<affiliation><nlm:aff id="A1">Centers for Disease Control and Prevention, Measles, Mumps, Rubella and Herpes Virus Laboratory Branch. 1600 Clifton Rd, C22, Atlanta, GA 30319.<email>mcoughlin@cdc.gov</email>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S." last="Prabhakar">Bellur S. Prabhakar</name>
<affiliation><nlm:aff id="A2">Department of Microbiology and Immunology MC790, College of Medicine, University of Illinois at Chicago, Room E705, 835 S. Wolcott Ave, Chicago, IL 60612.<email>bprabhak@uic.edu</email>
</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Reviews in Medical Virology</title>
<idno type="ISSN">1052-9276</idno>
<idno type="eISSN">1099-1654</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Antibodies, Monoclonal (isolation & purification)</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Neutralizing (isolation & purification)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibodies, Viral (isolation & purification)</term>
<term>Antiviral Agents (isolation & purification)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Epitopes (immunology)</term>
<term>Humans</term>
<term>Immunotherapy (methods)</term>
<term>Membrane Glycoproteins (antagonists & inhibitors)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Mice</term>
<term>Mice, Transgenic</term>
<term>Protein Binding</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (therapy)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Envelope Proteins (antagonists & inhibitors)</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (isolement et purification)</term>
<term>Anticorps monoclonaux (immunologie)</term>
<term>Anticorps monoclonaux (isolement et purification)</term>
<term>Anticorps neutralisants (immunologie)</term>
<term>Anticorps neutralisants (isolement et purification)</term>
<term>Antiviraux (isolement et purification)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (antagonistes et inhibiteurs)</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Humains</term>
<term>Immunothérapie ()</term>
<term>Liaison aux protéines</term>
<term>Protéines de l'enveloppe virale (antagonistes et inhibiteurs)</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Souris</term>
<term>Souris transgéniques</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Virus du SRAS (immunologie)</term>
<term>Épitopes (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Epitopes</term>
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps monoclonaux</term>
<term>Anticorps neutralisants</term>
<term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Virus du SRAS</term>
<term>Épitopes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps monoclonaux</term>
<term>Anticorps neutralisants</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Transgenic</term>
<term>Protein Binding</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Immunothérapie</term>
<term>Liaison aux protéines</term>
<term>Souris</term>
<term>Souris transgéniques</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Summary</title>
<p id="P1">The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) led to a rapid response not only to contain the outbreak but also to identify possible therapeutic interventions, including the generation of human monoclonal antibodies (hmAbs). Human mAbs may be used therapeutically without the drawbacks of chimeric or animal Abs. Several different methods have been used to generate SARS-CoV specific neutralizing hmAbs including the immunization of transgenic mice, cloning of small chain variable regions from naïve and convalescent patients, and the immortalization of convalescent B cells. Irrespective of the techniques used, the majority of hmAbs specifically reacted with the receptor binding domain (RBD) of the spike (S) protein and likely prevented receptor binding. However, several hmAbs that can bind to epitopes either within the RBD, located N terminal of the RBD or in the S2 domain and neutralize the virus with or without inhibiting receptor binding have been identified. Therapeutic utility of hmAbs has been further elucidated through the identification of potential combinations of hmAbs that could neutralize viral variants including escape mutants selected using hmAbs. These results suggest that a cocktail of hmAbs which can bind to unique epitopes and have different mechanisms of action might be of clinical utility against SARS-CoV infection, and indicate that a similar approach may be applied to treat other viral infections.</p>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002381 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002381 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Ncbi |étape= Curation |type= RBID |clé= PMC:3256278 |texte= Neutralizing Human Monoclonal Antibodies to Severe Acute Respiratory Syndrome Coronavirus: Target, Mechanism of Action and Therapeutic Potential }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:21905149" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |